Combined treatment and survival of medullary thyroid carcinoma patients

• Autorzy: Zenonas Baranauskas , Konstantinas Valuckas , Giedre Smailyte
• Języki publikacji: EN

Abstrakty

EN

The aim of this study is to analyze the impact of combined treatment (thyroidectomy and radiotherapy and radioactive iodine treatment) on patients’ long-term survival with medullary thyroid carcinoma. This is a retrospective study of 59 patients treated from 1977 to 2006 for medullary carcinoma at the Institute of Oncology in Vilnius, Lithuania. Survival was estimated by the Kaplan-Meier method. Univariate and multivariate Cox proportional hazard models were used to explore the association of prognostic factors with long-term survival. The survival of MTC patients was 88.0% (95% CI 68.0–88.9), 67.9% (95% CI 52.3–79.4) and 60.5% (95% CI 43.2–74.0), respectively, 5, 10 and 15 years after diagnosis. In survival analysis, only the type of surgery and lymph node involvement were found to be significant prognostic factors. The results of this study suggest that treatment with radioiodine and external beam radiotherapy do not improve significantly the long-term survival of surgically treated MTC patients.

Słowa kluczowe

EN

Medullary carcinoma; Thyroidectomy; External beam radiotherapy; 131I radiotherapy

• Czasopismo: Open Medicine
• Rocznik: 2010
• Tom: 5
• Numer: 4
• Strony: 426-430

Daty

wydano

2010-08-01

online

2010-05-30

Twórcy

autor

Zenonas Baranauskas

• Institute of Oncology, Vilnius University, Clinic of conservative tumour therapy, Santariskiu 1, LT-08660, Vilnius, Lithuania

autor

Konstantinas Valuckas

• Institute of Oncology, Vilnius University, Clinic of conservative tumour therapy, Santariskiu 1, LT-08660, Vilnius, Lithuania

autor

Giedre Smailyte

• Institute of Oncology, Vilnius University, Scientific Research Centre, P. Baublio 3B, LT-08406, Vilnius, Lithuania,

Bibliografia

• [1] Cohen M.S., Molley J.F., Surgical treatment of medullary thyroid carcinoma, J. Intern. Med., 2003, 253, 616–626 http://dx.doi.org/10.1046/j.1365-2796.2003.01166.x[Crossref]
• [2] Yen T.W., Shapiro S.E., Gagel R.F., Sherman S.I., Lee J.E., Evans D.B., Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients, Surgery, 2003, 134, 890–899 http://dx.doi.org/10.1016/S0039-6060(03)00408-2[Crossref]
• [3] Ball D.W., DeBustos A.C., Thyroid, 8th ed., Philadelphia, Lippincott Williams & Wilkins, 2000
• [4] Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.F., Gharib H., et al., Medullary thyroid cancer: management guidelines of American Thyroid Association, Thyroid, 2009, 19, 565–612 http://dx.doi.org/10.1089/thy.2008.0403[WoS][Crossref]
• [5] Bergholm U., Bergstrom R., Ekbom A., Long-term follow-up of patients with medullary carcinoma of the thyroid, Cancer, 1997, 79, 132–138 http://dx.doi.org/10.1002/(SICI)1097-0142(19970101)79:1<132::AID-CNCR19>3.0.CO;2-5[Crossref]
• [6] de Groot J.W., Plukker J.T., Wolffenbuttel B.H., Wiggers T., Sluiter W.J., Links T.P., Determinants of life expectancy in medullary thyroid cancer: age does not matter, Clin. Endocrinol., 2006, 65, 729–736 http://dx.doi.org/10.1111/j.1365-2265.2006.02659.x[Crossref]
• [7] Roman S., Lin R., Sosa J.A., Prognosis of medullary thyroid carcinoma, Cancer, 2006, 107, 2134–2142 http://dx.doi.org/10.1002/cncr.22244[Crossref]
• [8] Cupisti K., Wolf A., Raffel A., Schott M., Miersch D., Yang Q., et al., Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years, Ann. Surg., 2007, 246, 815–821 http://dx.doi.org/10.1097/SLA.0b013e31813e66b9[Crossref]
• [9] Rendl G., Manzl M., Hitzl W., Sungler P., Pirich C., Long-term prognosis of medullary thyoid carcinoma, Clin. Endocrinol., 2008, 69, 497–505
• [10] Scollo C., Baudin E., Travagli J.P., Caillou B., Bellon N., Leboulleux S., et al., Rationale for central and bilateral lymph node dissection in sporadic hereditary medullary thyroid cancer, J. Clin. Endocrinol. Metab., 2003, 88, 2070–2075 http://dx.doi.org/10.1210/jc.2002-021713[Crossref]
• [11] Moley J.F., DeBenedetti M.K., Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extend of node dissection, Ann. Surg., 1999, 229, 880–887
• [12] Leboulleux S., Baudin E., Travagli J.P., Schlumberger M., Medullary thyroid carcinoma, Clin. Endocrinol., 2004, 61, 299–310
• [13] Pelizzo M.R., Boschin I.M., Bernante P., Toniato A., Piotto A., Pagetta C., et al., Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients, Eur. J. Surg. Oncol., 2007, 33, 493–497 http://dx.doi.org/10.1016/j.ejso.2006.10.021[Crossref]
• [14] Schwartz D.L., Rana V., Shaw S., Yazbeck C., Ang K.K., Morrison W.H., et al., Post radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era, Head Neck, 2008, 883–888
• [15] Tubiana M., Haddad E., Schlumberger M., Hill C., Rougier P., Sarrazin D., External radiotherapy in thyroid cancer, Cancer, 1985, 55, 2062–2071 http://dx.doi.org/10.1002/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO;2-O[Crossref]
• [16] Schlumberger M., Gardet P., External radiotherapy and chemotherapy in MTC patients, In: Calmettes C., Guliana J., M., (Eds.), Medullary Thyroid Carcinoma, Colloques INSERM/John Libbey Eurotext Ltd, 1991
• [17] Brierley J., Tsang R., Simpson W.J., Gospodarowicz M., Sutcliffe S., Panzarella T., Medullary thyroid cancer: analyses of survival and prognostic factors the role of radiation therapy in local control, Thyroid, 1996, 6, 305–310 http://dx.doi.org/10.1089/thy.1996.6.305[Crossref]
• [18] Fife K.M., Bower M., Harmer C.L., Medullary thyroid cancer: the role of radiotherapy in local control, Eur. J. Surg. Oncol., 1996, 22, 588–591 http://dx.doi.org/10.1016/S0748-7983(96)92294-5[Crossref]
• [19] Fersht N., Vini L., A’Hern R., Harmer C., The role of radiothrepy in the management of elevated calcitonin after surgery for medullary thyroid cancer, Thyroid, 2001, 11, 1161–1168 http://dx.doi.org/10.1089/10507250152741019[Crossref]
• [20] Hellman D.E., Kartchner M., Van Antwerp J.D., Salmon S.E., Patton D.D., O’Mara R., Radioiodine in the treatment of medullary carcinoma of the thyroid, J. Clin. Endocrinol. Metab., 1979, 48, 451–455 http://dx.doi.org/10.1210/jcem-48-3-451[Crossref]
• [21] Deftos L.J., Stein M.F., Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma, J. Clin. Endocrinol. Metab., 1980, 50, 967–968 http://dx.doi.org/10.1210/jcem-50-5-967[Crossref]
• [22] Finny P., Jacob J.J., Thomas N., Philip J., Rajarathnam S., Oommen R. et al., Medullary thyroid carcinoma: a 20-year experience from centre in South India. ANZ J. Surg., 2007, 77, 130–134 http://dx.doi.org/10.1111/j.1445-2197.2006.03992.x[Crossref]

Identyfikatory

DOI

10.2478/s11536-010-0023-8